Le Lézard
Classified in: Health
Subjects: TDS, FVT

Imprimis Pharmaceuticals to Present at the Canaccord Genuity 38th Annual Growth Conference on August 9, 2018

SAN DIEGO, July 18, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced that its Chief Executive Officer, Mark L. Baum, will present an update on the company's business at the Canaccord Genuity 38th Annual Growth Conference on Thursday, August 9th, 2018 at 11:00 a.m. ET in the London Room at the InterContinental Boston Hotel in Boston, MA.  The presentation will be broadcast via a live webcast and an archive of the presentation will be available for 365 days following the event.  The webcast can be accessed by clicking on the following link: http://wsw.com/webcast/canaccord30/immy/.  The Investor Relations section of the Imprimis website will have a link to the webcast as well, which can be found by clicking here.  Mark and Chief Financial Officer, Andrew Boll, will be hosting one-on-one meetings at the conference and attendees can contact their Canaccord representative to arrange a meeting.

Imprimis Pharmaceuticals Logo (PRNewsFoto/Imprimis Pharmaceuticals)


Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a rapidly growing commercial-stage pharmaceutical company based in San Diego, California.  In addition to owning the nation's leading ophthalmology pharmaceutical compounding business, ImprimisRx, the Company holds large equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals and Melt Pharmaceuticals, companies originally founded as subsidiaries of Imprimis.  The Company also owns royalty rights in certain 505(b)(2) drug candidates being developed by Eton, Surface and Melt.  For more information about Imprimis, please visit the Investor Relations section of the corporate website by clicking here.


This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to make commercially available our compounded formulations and technologies in a timely manner or at all; physician interest in prescribing our formulations; risks related to our compounding pharmacy operations; our ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of our formulations; our ability to obtain intellectual property protection for our assets; our ability to accurately estimate our expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for our technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

No Imprimis compounded formulation is FDA-approved. Other than drugs compounded at a registered outsourcing facility, all Imprimis compounded formulations require a prescription for an individually identified patient consistent with federal and state laws.


Investor Contact:
Jon Patton

SOURCE Imprimis Pharmaceuticals, Inc.

These press releases may also interest you

at 20:53
Hiku Brands Company Ltd. ("Hiku" or the "Company") is excited to announce that we have entered into a supply agreement with the Ontario Cannabis Store to supply branded cannabis online starting October 17, 2018. The...

at 19:02
Canopy Growth Corporation (the "Company" or "Canopy Growth"), through its wholly-owned subsidiary Tweed Inc., has been selected as an approved supplier by the Ontario Cannabis Store ("OCS") to supply a wide variety of cannabis products through its...

at 18:16
OrthoAtlanta is proud to serve as the official orthopedic and sports medicine provider to the 2018 Chick-fil-A Kickoff Game, a role it has held since the inaugural 2008 game. As the nation's longest-running kickoff game, the annual Chick-fil-A...

at 18:00
AUSTIN, Texas, Aug. 20, 2018 /PRNewswire-PRWeb/ -- Edward Buckingham, MD is proud to announce that his practice, Buckingham Center for Facial Plastic Surgery, has been awarded Allergan's Diamond Status for 2018. This prestigious honor is reserved for...

at 18:00
CannaRoyalty Corp. ("CannaRoyalty" or the "Company"), a leading North American cannabis products and brands company, today announced that it plans to release its financial results for the second quarter ended June 30, 2018 on Thursday, August 23,...

at 17:30
IMMUNOPRECISE ANTIBODIES LTD. ("ImmunoPrecise" or "IPA") announces that Mr. Guy Champagne, has resigned from his position as a director, effective immediately, and will be joining ImmunoPrecise's Advisory Board.  The Board of Directors would like to...

News published on 18 july 2018 at 07:30 and distributed by: